scispace - formally typeset
E

Eric J. Topol

Researcher at Scripps Health

Publications -  1406
Citations -  162373

Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.

Papers
More filters
Journal ArticleDOI

Initial report of the National Registry of Elective Cardiopulmonary Bypass Supported Coronary Angioplasty.

TL;DR: A National Registry of 14 centers performing elective supported angioplasty was formed to collate the initial experience with high risk patients and a cardiopulmonary bypass system capable of providing up to 6 liters/min output was employed prophylactically.
Journal ArticleDOI

Need to Test the Arterial Inflammation Hypothesis

TL;DR: A prospective study of patients with established cardiovascular disease and elevated baseline CRP in which incremental pharmacotherapy would be guided by reassessments of the CRP marker could allow formulation of a rational therapeutic strategy instead of an approach of “polypharmacy” for these patients.
Journal ArticleDOI

Effects of Antisense c-myb Oligonucleotides on Vascular Smooth Muscle Cell Proliferation and Response to Vessel Wall Injury

TL;DR: In vitro experiments using identical culture conditions in rat, dog, and human aortic smooth muscle cells failed to show specificity as well as consistency in growth inhibitory effects that could be attributed to an antisense mechanism, pointing to the potential nonspecificity and lack of consistency of the antisense oligonucleotide to c-myb in vitro and in vivo.
Journal ArticleDOI

High-Definition Medicine

TL;DR: This review will examine the core disciplines that enable high-definition medicine and project how these technologies will alter the future of medicine.
Journal ArticleDOI

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.

TL;DR: Abciximab treatment reduced all-cause mortality by about 20% during long-term follow-up after percutaneous coronary intervention as mentioned in this paper, and the absolute survival benefit appeared to increase over time.